Janusz Klatka1, Ewelina Grywalska2, Anna Hymos1, Małgorzata Guz3, Krzysztof Polberg4, Jacek Roliński2, Andrzej Stepulak5. 1. Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland. 2. Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland. 3. Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland. 4. Department of Otolaryngology, MSW Hospital, Lublin, Poland. 5. Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland andrzej.stepulak@umlub.pl.
Abstract
BACKGROUND/AIM: The aim of this study was to analyze whether inhibition of cyclooxygenase-2 by celecoxib and the subsequent enhancement in the proliferation of natural killer T (NKT) cells could play a role in dendritic cell (DC)-based laryngeal cancer (LC) immunotherapy. PATIENTS AND METHODS: Peripheral blood mononuclear cells were obtained from 48 male patients diagnosed with LC and 30 control patients without cancer disease. Neoplastic cell lysate preparations were made from cancer tissues obtained after surgery and used for in vitro DCs generation. NKT cells proliferation assay was performed based on 3H-thymidine incorporation assay. RESULTS: An increased proliferation of NKT cells was obtained from control patients compared to NKT cells obtained from LC patients regardless of the type of stimulation or treatment. In the patient group diagnosed with LC, COX-2 inhibition resulted in a significantly enhanced proliferation of NKT cells when stimulated with autologous DCs than NKT cells stimulated with DCs without COX-2 inhibition. These correlations were not present in the control group. Higher proliferation rate of NKT cells was also observed in non-metastatic and highly differentiated LC, which was independent of the type of stimulation or treatment. CONCLUSION: COX-2 inhibition could be regarded as immunotherapy-enhancing tool in patients with LC. Copyright
BACKGROUND/AIM: The aim of this study was to analyze whether inhibition of cyclooxygenase-2 by celecoxib and the subsequent enhancement in the proliferation of natural killer T (NKT) cells could play a role in dendritic cell (DC)-based laryngeal cancer (LC) immunotherapy. PATIENTS AND METHODS: Peripheral blood mononuclear cells were obtained from 48 male patients diagnosed with LC and 30 control patients without cancer disease. Neoplastic cell lysate preparations were made from cancer tissues obtained after surgery and used for in vitro DCs generation. NKT cells proliferation assay was performed based on 3H-thymidine incorporation assay. RESULTS: An increased proliferation of NKT cells was obtained from control patients compared to NKT cells obtained from LC patients regardless of the type of stimulation or treatment. In the patient group diagnosed with LC, COX-2 inhibition resulted in a significantly enhanced proliferation of NKT cells when stimulated with autologous DCs than NKT cells stimulated with DCs without COX-2 inhibition. These correlations were not present in the control group. Higher proliferation rate of NKT cells was also observed in non-metastatic and highly differentiated LC, which was independent of the type of stimulation or treatment. CONCLUSION:COX-2 inhibition could be regarded as immunotherapy-enhancing tool in patients with LC. Copyright
Authors: Preeti Kanikarla-Marie; Michael Lam; Alexey V Sorokin; Michael J Overman; Scott Kopetz; David G Menter Journal: Front Oncol Date: 2018-04-20 Impact factor: 6.244